• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Adverum Biotechnologies Inc.

    2/27/25 4:59:47 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email
    S-8 1 d871552ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-  

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Adverum Biotechnologies, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   20-5258327

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    100 Cardinal Way

    Redwood City, California

      94063
    (Address of registrant’s principal executive offices)   Zip code

     

     

    2017 Inducement Plan, as amended and restated

    (Full title of the plans)

     

     

    Linda Rubinstein

    Chief Financial Officer

    Adverum Biotechnologies, Inc.

    100 Cardinal Way

    Redwood City, California 94063

    (650) 656-9323

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Jason Kent

    Julia Boesch

    Cooley LLP

    55 Hudson Yards

    New York, NY 10001

    (212) 479-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    Explanatory Note

    This Registration Statement on Form S-8 (this “Registration Statement”) registers an additional 250,000 shares of the common stock, par value $0.0001 per share, of Adverum Biotechnologies, Inc. (“Common Stock”) that may be issued and sold under the Adverum Biotechnologies, Inc. 2017 Inducement Plan, as amended and restated (“2017 Plan”).

    Pursuant to General Instruction E of Form S-8, this registration statement incorporates by reference the contents of the registration statements on Form S-8 relating to the 2017 Plan filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on October 11, 2017 (File No. 333-220894), March 7, 2019  ((File No. 333-230138) as amended by  Post-Effective Amendment No. 1 thereto filed on March 12, 2019), August  8, 2019 (File No. 333-233135), August  10, 2020 (File No. 333-243761), March  1, 2021 (File No. 333-253727) and December  19, 2024 (File No. 333-283935).


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act, and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents have been filed by us with the SEC and are incorporated herein by reference:

     

      •  

    The contents of the earlier registration statements on Form S-8 relating to the 2017 Plan, previously filed with the SEC on October 11, 2017 (File No. 333-220894), March 7, 2019 ((File No. 333-230138) as amended by  Post-Effective Amendment No. 1 thereto filed on March 12, 2019), August  8, 2019 (File No. 333-233135), August  10, 2020 (File No. 333-243761), March  1, 2021 (File No. 333-253727) and December  19, 2024 (File No. 333-283935);

     

      •  

    our Annual Report on Form 10-K for the year ended December 31, 2023 which was filed with the SEC on March 18, 2024 (our “Annual Report”); and

     

      •  

    our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024 filed with the SEC on May  9, 2024, August  12, 2024 and November 4, 2024;

     

      •  

    our Current Reports on Form 8-K filed with the SEC on February  5, 2024, February 6, 2024,  February 8, 2024,  March 20, 2024,  June 11, 2024,  June  18, 2024, July 17, 2024 and November  18, 2024, to the extent the information in such reports is filed and not furnished;

     

      •  

    the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July  28, 2014, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.2 to our Annual Report for the year ended December 31, 2021, which was filed with the SEC on March 1, 2021.

    All documents subsequently filed by the us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

    For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8. Exhibits.

    Exhibit Index

     

                     Incorporated by Reference  

    Exhibit

    Number

      

    Exhibit Description

       Form      SEC
    File No.
         Exhibit Number     

    Date

       Filed
    Herewith
     
    4.1    Restated Certificate of Incorporation.      10-Q        001-36579        3.1      November 4, 2024   
    4.2    Amended and Restated Bylaws.      8-K        001-36579        3.1      June 29, 2020   


    5.1    Opinion of Cooley LLP.                  X  
    23.1    Consent of Independent Registered Public Accounting Firm.                  X  
    23.2    Consent of Cooley LLP (included in Exhibit 5.1).                  X  
    24.1    Power of Attorney (included on signature page hereto).                  X  
    99.1    2017 Inducement Plan, as amended and restated.                  X  
    107    Filing Fee Table.                  X  


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California on February 27, 2025.

     

    Adverum Biotechnologies, Inc.
    By:  

    /s/ Laurent Fischer

      Laurent Fischer, M.D.
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laurent Fischer and Linda Rubinstein, and each one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated.

     

    SIGNATURE

         

    TITLE

     

    DATE

    /s/ Laurent Fischer

        President, Chief Executive Officer and Director   February 27, 2025
    Laurent Fischer, M.D.     (Principal Executive Officer)  

    /s/ Linda Rubinstein

        Chief Financial Officer   February 27, 2025
    Linda Rubinstein     (Principal Financial Officer and Principal Accounting Officer)  

    /s/ Patrick Machado

        Chairman of the Board   February 27, 2025
    Patrick Machado, J.D.      

    /s/ Soo Hong

        Director   February 27, 2025
    Soo Hong, M.B.A      

    /s/ Szilárd Kiss

        Director   February 27, 2025
    Szilárd Kiss, M.D.      

    /s/ Mark Lupher

        Director   February 27, 2025
    Mark Lupher, Ph.D.      


    /s/ C. David Nicholson

        Director   February 27, 2025
    C. David Nicholson, Ph.D.      

    /s/ James Scopa

        Director   February 27, 2025
    James Scopa, J.D., M.B.A.      

    /s/ Dawn Svoronos

        Director   February 27, 2025
    Dawn Svoronos      

    /s/ Reed Tuckson

        Director   February 27, 2025
    Reed Tuckson, M.D.      

    /s/ Scott Whitcup

        Director   February 27, 2025
    Scott Whitcup, M.D.      
    Get the next $ADVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADVM

    DatePrice TargetRatingAnalyst
    6/25/2024$25.00Outperform
    Oppenheimer
    4/30/2024$30.00Buy
    H.C. Wainwright
    7/7/2022$4.00Hold → Buy
    Truist
    7/23/2021Hold → Neutral
    Cantor Fitzgerald
    7/23/2021$23.00 → $3.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2021$5.00 → $2.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common

      5/2/25 4:01:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

      REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. "We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a potential best-in-class, one-and-done gene therapy. Ixo-vec offers the potential for life-long vision preservation and a favorable safety profile and is overwhelmingly preferred by patients over tod

      4/15/25 7:40:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $3.83 per share, Adverum's closing trading price on the grant date, and will vest over four years,

      4/4/25 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Financials

    Live finance-specific insights

    See more
    • Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

      REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

      7/10/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

      - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

      2/1/24 5:30:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

      REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

      12/7/23 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adverum Biotechnologies Inc.

      SCHEDULE 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      5/6/25 9:15:54 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adverum Biotechnologies Inc.

      DEFA14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      4/28/25 4:02:59 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Adverum Biotechnologies Inc.

      DEF 14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      4/28/25 4:01:46 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:57:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:40:56 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 4:05:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Leadership Updates

    Live Leadership Updates

    See more
    • Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

      - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

      11/4/24 4:39:45 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

      REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

      10/16/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

      - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reporte

      8/12/24 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Adverum Biotech with a new price target

      Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

      6/25/24 8:10:21 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

      H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00

      4/30/24 6:15:49 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotech upgraded by Truist with a new price target

      Truist upgraded Adverum Biotech from Hold to Buy and set a new price target of $4.00

      7/7/22 7:11:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care